Thursday, August 20, 2026
RSS

Markets & Money

Aurora Cannabis Faces Hostile Takeover: What It Means for Investors

Aurora Cannabis is confronted with a hostile takeover bid from Curaleaf, raising questions about the future of the North American cannabis sector.

By Marcus Rivera • August 19, 2026
Pharmaceutical

Merck's Breakthrough: Analysts React to Positive Drug Trial News

Analysts are optimistic about Merck's future after a 7.4% surge in shares following positive trial results.

Sarah Chen • Aug 19
Markets & Money

Curaleaf's Hostile Bid for Aurora: Implications for Cannabis Investors

Curaleaf's hostile takeover bid for Aurora Cannabis raises critical questions for investors amid ongoing negotiations.

Marcus Rivera • Aug 19
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Pharmaceutical

Amylyx Pharmaceuticals' 55% Surge: A Turning Point for Avexitide and Biotech Investors

Amylyx Pharmaceuticals saw a 55% surge following positive results from its avexitide trial, signaling strong investor co…

Sarah Chen • Aug 19, 2026
Pharmaceutical

Moderna's Historic Phase 3 Cancer Vaccine Triumph: What Investors Need to Know

Moderna's stock saw a significant surge following its Phase 3 cancer vaccine success, indicating a pivotal moment for in…

James McAllister • Aug 19, 2026
Pharmaceutical

Curaleaf's Hostile Takeover Bid: A Game Changer for the Cannabis Industry

Curaleaf's $4/share bid for Aurora Cannabis could reshape the cannabis landscape, creating ripples across the US and Can…

Marcus Rivera • Aug 18, 2026
Pharmaceutical

Hims & Hers Faces FTC Lawsuit: Implications for Telehealth Investors

Hims & Hers faces regulatory scrutiny, prompting a closer look at its telehealth business model and market sentiment.

Sarah Chen • Aug 18, 2026
Pharmaceutical

BioMarin's Strategic Acquisition: What It Means for Investors

BioMarin's $275M acquisition of Alesta Therapeutics could enhance its rare disease focus and shareholder value.

James McAllister • Aug 18, 2026
Markets & Money

30-Year Treasury Yield at 19-Year High: What It Means for US and Canadian Markets

The 30-year US Treasury yield has hit a 19-year high, reshaping market landscapes and investor strategies.

Marcus Rivera • Aug 18, 2026
Pharmaceutical

Curaleaf's Hostile Bid for Aurora Cannabis: Implications for North American Cannabis Investors

Curaleaf's $4/share bid for Aurora Cannabis signals major changes in the cannabis sector, impacting investors across the…

Sarah Chen • Aug 18, 2026
Pharmaceutical

Amylyx Pharmaceuticals' Avexitide Phase 3 Success: What Investors Need to Know

Amylyx's Phase 3 success with avexitide shows promise for investors, especially amid past setbacks.

James McAllister • Aug 18, 2026
Tech

Nvidia's Strategic Move: Financing OpenAI's Data Center in Ohio

Nvidia's financing of OpenAI's data center marks a pivotal moment in AI infrastructure and investor sentiment.

Marcus Rivera • Aug 17, 2026